SBIR-STTR Award

Purine Analogs as Novel Treatment for Skin Disease
Award last edited on: 8/10/04

Sponsored Program
SBIR
Awarding Agency
NIH : NIAID
Total Award Amount
$99,278
Award Phase
1
Solicitation Topic Code
-----

Principal Investigator
Chantal Roullet

Company Information

Columbia Biotechnologies Corporation

PO Box 65787
Vancouver, WA 98665
   (360) 326-4889
   info@columbiabiotech.com
   www.columbiabiotech.com
Location: Single
Congr. District: 03
County: Clark

Phase I

Contract Number: 1R43AI060334-01
Start Date: 00/00/00    Completed: 00/00/00
Phase I year
2004
Phase I Amount
$99,278
Many human skin diseases display a hyperproliferative or proliferative epidermis, or cutaneous inflammation, or combinations of these two pathological characteristics (e. g., psoriasis). As an example, the keratinocytes of psoriatic epidermis are both hyperproliferative and produce elevated levels of Amphiregulin, IL-8, IL-1alpha and TNFalpha cytokines that may both attract and activate inflammatory cells, and promote psoriatic epidermal keratinocyte hyperproliferation. Additionally, the aberrant activity of the immune system may direct the mitogenic activation of these cells by activating an endogenous epidermal growth factor (EGF) pathway in the psoriatic epidermal keratinocytes. In addition to treating this pathology with immunosuppressive therapies, it is also thought that an effective blockade of EGF signaling could also be of therapeutic benefit. Endogenous purine-related compounds have been shown to dampen the inflammatory state by inhibiting the activity of immune cells. We have demonstrated that these naturally occurring purine-related compounds can reversibly inhibit the EGF receptor-dependent proliferation of both normal and psoriatic keratinocytes in vitro. We have also shown that these compounds also suppress the expression of cytokines such as IL-8, IL-1alpha and TNFalpha which are expressed in keratinocyte cell cultures treated with phorbol ester. We have recently demonstrated that a previously synthesized, non-naturally occurring purine-related analog inhibits both the proliferation of cultured human keratinocytes and phorbol-ester-induced keratinocyte inflammatory cytokine expression. Our proposed investigation will examine activity of this analog, and related purine analogs, on both human keratinocyte cultures, and intact human skin organ culture models. The results of the proposed study will determine whether these compounds might represent candidate non-steroidal drugs for further preclinical testing as therapeutics for inflammatory-proliferative skin disease states (e. g., psoriasis).

Thesaurus Terms:
adenine analog, cell proliferation, drug design /synthesis /production, epidermal growth factor, keratinocyte, psoriasis, skin disorder chemotherapy, skin hyperplasia combinatorial chemistry, topical drug application clinical research, human tissue, tissue /cell culture

Phase II

Contract Number: ----------
Start Date: 00/00/00    Completed: 00/00/00
Phase II year
----
Phase II Amount
----